Haemonetics Corporation (HAE) Expected to Post Quarterly Sales of $219.67 Million

Wall Street brokerages expect that Haemonetics Corporation (NYSE:HAE) will announce sales of $219.67 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Haemonetics Corporation’s earnings. The lowest sales estimate is $216.91 million and the highest is $224.09 million. Haemonetics Corporation posted sales of $220.25 million during the same quarter last year, which suggests a negative year over year growth rate of 0.3%. The company is scheduled to announce its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Haemonetics Corporation will report full year sales of $219.67 million for the current financial year, with estimates ranging from $884.60 million to $896.99 million. For the next year, analysts forecast that the business will post sales of $925.61 million per share, with estimates ranging from $906.40 million to $945.11 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Haemonetics Corporation.

Haemonetics Corporation (NYSE:HAE) last issued its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 EPS for the quarter, beating the consensus estimate of $0.31 by $0.02. The company had revenue of $211 million during the quarter, compared to analysts’ expectations of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 EPS.

A number of analysts have recently commented on HAE shares. BidaskClub lowered shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research note on Friday, June 23rd. Barrington Research upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a research note on Tuesday, August 8th. Zacks Investment Research upgraded shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Thursday, August 24th. TheStreet upgraded shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Haemonetics Corporation in a research note on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $40.71.

A number of large investors have recently modified their holdings of HAE. Shine Investment Advisory Services Inc. purchased a new position in Haemonetics Corporation during the second quarter valued at approximately $132,000. Riverhead Capital Management LLC lifted its holdings in Haemonetics Corporation by 79.3% during the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 1,507 shares in the last quarter. Pacad Investment Ltd. purchased a new position in Haemonetics Corporation during the second quarter valued at approximately $174,000. Ameritas Investment Partners Inc. purchased a new position in Haemonetics Corporation during the first quarter valued at approximately $179,000. Finally, Shelton Capital Management purchased a new position in Haemonetics Corporation during the second quarter valued at approximately $204,000.

Shares of Haemonetics Corporation (NYSE HAE) opened at 43.05 on Monday. The firm’s 50 day moving average is $41.69 and its 200 day moving average is $40.64. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $43.77. The company has a market cap of $2.26 billion, a PE ratio of 559.09 and a beta of 0.89.

COPYRIGHT VIOLATION NOTICE: “Haemonetics Corporation (HAE) Expected to Post Quarterly Sales of $219.67 Million” was posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://weekherald.com/2017/09/18/haemonetics-corporation-hae-expected-to-post-quarterly-sales-of-219-67-million.html.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get a free copy of the Zacks research report on Haemonetics Corporation (HAE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply